{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:23:45Z","timestamp":1790936625679,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,6,29]],"date-time":"2005-06-29T00:00:00Z","timestamp":1120003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s00213-005-0033-4","type":"journal-article","created":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T12:56:00Z","timestamp":1119963360000},"page":"84-94","source":"Crossref","is-referenced-by-count":18,"title":["Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced \u201cearly onset\u201d vacuous chewing in rats: implications for antipsychotic drug therapy"],"prefix":"10.1007","volume":"182","author":[{"given":"William A.","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Bieganski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Mignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,6,29]]},"reference":[{"key":"33_CR1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1471-4159.1984.tb05375.x","volume":"43","author":"G Battaglia","year":"1984","unstructured":"Battaglia G, Shannon M, Titeler M (1984) Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors. J Neurochem 43:1213\u20131219","journal-title":"J Neurochem"},{"key":"33_CR2","first-page":"863","volume":"55","author":"KA Berg","year":"1999","unstructured":"Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP (1999) Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 55:863\u2013872","journal-title":"Mol Pharmacol"},{"key":"33_CR3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"key":"33_CR4","first-page":"604","volume":"38","author":"T Branchek","year":"1990","unstructured":"Branchek T, Adham N, Macchi M, Kao HT, Hartig PR (1990) [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol Pharmacol 38:604\u2013609","journal-title":"Mol Pharmacol"},{"key":"33_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-002-1247-3","volume":"165","author":"BB Carlson","year":"2003","unstructured":"Carlson BB, Wisniecki A, Salamone JD (2003) Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of parkinsonian tremor. Psychopharmacology (Berl) 165:229\u2013237","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 9","key":"33_CR6","first-page":"25","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65(Suppl 9):25\u201328","journal-title":"J Clin Psychiatry"},{"key":"33_CR7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0028-3908(99)00086-6","volume":"39","author":"DA Clemett","year":"2000","unstructured":"Clemett DA, Punhani T, Duxon MS, Blackburn TP, Fone KC (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123\u2013132","journal-title":"Neuropharmacology"},{"key":"33_CR8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archpedi.158.8.753","volume":"158","author":"WO Cooper","year":"2004","unstructured":"Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA (2004) New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753\u2013759","journal-title":"Arch Pediatr Adolesc Med"},{"key":"33_CR9","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1523\/JNEUROSCI.20-13-05170.2000","volume":"20","author":"P Deurwaerdere De","year":"2000","unstructured":"De Deurwaerdere P, Chesselet MF (2000) Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J Neurosci 20:5170\u20135178","journal-title":"J Neurosci"},{"key":"33_CR10","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","volume":"24","author":"P Deurwaerdere De","year":"2004","unstructured":"De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235\u20133241","journal-title":"J Neurosci"},{"key":"33_CR11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0306-4522(98)00655-1","volume":"91","author":"G Giovanni Di","year":"1999","unstructured":"Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin-2C\/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587\u2013597","journal-title":"Neuroscience"},{"key":"33_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0306-4522(95)00548-X","volume":"72","author":"K Eberle-Wang","year":"1996","unstructured":"Eberle-Wang K, Lucki I, Chesselet MF (1996) A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72:117\u2013128","journal-title":"Neuroscience"},{"key":"33_CR13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1096-9861(19970728)384:2<233::AID-CNE5>3.0.CO;2-2","volume":"384","author":"K Eberle-Wang","year":"1997","unstructured":"Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997) Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384:233\u2013247","journal-title":"J Comp Neurol"},{"key":"33_CR14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF02245101","volume":"117","author":"MF Egan","year":"1995","unstructured":"Egan MF, Hyde TM, Kleinman JE, Wyatt RJ (1995) Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology (Berl) 117:74\u201381","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02806012","volume":"127","author":"MF Egan","year":"1996","unstructured":"Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl) 127:337\u2013345","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR16","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/jm00014a004","volume":"38","author":"IT Forbes","year":"1995","unstructured":"Forbes IT, Ham P, Booth DH, Martin RT, Thompson M, Baxter GS, Blackburn TP, Glen A, Kennett GA, Wood MD (1995) 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C\/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity. J Med Chem 38:2524\u20132530","journal-title":"J Med Chem"},{"key":"33_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/jm00396a003","volume":"31","author":"RA Glennon","year":"1988","unstructured":"Glennon RA, Seggel MR, Soine WH, Herrick-Davis K, Lyon RA, Titeler M (1988) [125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors. J Med Chem 31:5\u20137","journal-title":"J Med Chem"},{"key":"33_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-3057(92)90383-Q","volume":"41","author":"L Gong","year":"1992","unstructured":"Gong L, Kostrzewa RM (1992) Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol Biochem Behav 41:621\u2013623","journal-title":"Pharmacol Biochem Behav"},{"key":"33_CR19","first-page":"1000","volume":"261","author":"L Gong","year":"1992","unstructured":"Gong L, Kostrzewa RM, Fuller RW, Perry KW (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 261:1000\u20131007","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-3806(93)90211-R","volume":"76","author":"L Gong","year":"1993","unstructured":"Gong L, Kostrzewa RM, Perry KW, Fuller RW (1993) Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Brain Res Dev Brain Res 76:233\u2013238","journal-title":"Brain Res Dev Brain Res"},{"key":"33_CR21","first-page":"335","volume":"3","author":"P Hartig","year":"1990","unstructured":"Hartig P, Kao HT, Macchi M, Adham N, Zgombick J, Weinshank R, Branchek T (1990) The molecular biology of serotonin receptors. An overview. Neuropsychopharmacology 3:335\u2013347","journal-title":"Neuropsychopharmacology"},{"key":"33_CR22","first-page":"226","volume":"295","author":"K Herrick-Davis","year":"2000","unstructured":"Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226\u2013232","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR23","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ajhp\/54.21.2461","volume":"54","author":"LC Holloman","year":"1997","unstructured":"Holloman LC, Marder SR (1997) Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health-Syst Pharm 54:2461\u20132477","journal-title":"Am J Health-Syst Pharm"},{"key":"33_CR24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, Wahlbeck K (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 161:160\u2013163","journal-title":"Am J Psychiatry"},{"key":"33_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00178722","volume":"354","author":"MP Johnson","year":"1996","unstructured":"Johnson MP, Siegel BW, Carr AA (1996) [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand. Naunyn-Schmiedeberg's Arch Pharmacol 354:205\u2013209","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"Suppl 9","key":"33_CR26","first-page":"16","volume":"65","author":"JM Kane","year":"2004","unstructured":"Kane JM (2004) Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 65(Suppl 9):16\u201320","journal-title":"J Clin Psychiatry"},{"key":"33_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02245603","volume":"124","author":"S Kapur","year":"1996","unstructured":"Kapur S (1996) 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology (Berl) 124:35\u201339","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360\u2013369","journal-title":"Am J Psychiatry"},{"key":"33_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/070674370004500302","volume":"45","author":"S Kapur","year":"2000","unstructured":"Kapur S, Wadenberg ML, Remington G (2000) Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry 45:241\u2013246","journal-title":"Can J Psychiatry"},{"key":"33_CR30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1525-8610(04)70130-9","volume":"5","author":"JW Kasckow","year":"2004","unstructured":"Kasckow JW, Mulchahey JJ, Mohamed S (2004) The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting. J Am Med Dir Assoc 5:242\u2013248","journal-title":"J Am Med Dir Assoc"},{"key":"33_CR31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2004.02.012","volume":"25","author":"T Kenakin","year":"2004","unstructured":"Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186\u2013192","journal-title":"Trends Pharmacol Sci"},{"key":"33_CR32","first-page":"1262","volume":"264","author":"M Kuoppamaki","year":"1993","unstructured":"Kuoppamaki M, Seppala T, Syvalahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262\u20131267","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0893-133X(95)00049-J","volume":"13","author":"M Kuoppamaki","year":"1995","unstructured":"Kuoppamaki M, Palvimaki EP, Hietala J, Syvalahti E (1995) Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13:139\u2013150","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl","key":"33_CR34","first-page":"5","volume":"55","author":"JE Leysen","year":"1994","unstructured":"Leysen JE, Janssen PM, Megens AA, Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55(Suppl):5\u201312","journal-title":"J Clin Psychiatry"},{"key":"33_CR35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0028-3908(98)00102-6","volume":"37","author":"JF Lopez-Gimenez","year":"1998","unstructured":"Lopez-Gimenez JF, Vilaro MT, Palacios JM, Mengod G (1998) [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology 37:1147\u20131158","journal-title":"Neuropharmacology"},{"key":"33_CR36","first-page":"194","volume":"31","author":"RA Lyon","year":"1987","unstructured":"Lyon RA, Davis KH, Titeler M (1987) 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194\u2013199","journal-title":"Mol Pharmacol"},{"key":"33_CR37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1460-9568.2002.01944.x","volume":"15","author":"G Marchese","year":"2002","unstructured":"Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P, Gessa GL, Pani L (2002) Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to \u201cearly onset\u201d vacuous chewing. Eur J Neurosci 15:1187\u20131196","journal-title":"Eur J Neurosci"},{"key":"33_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0166-4328(03)00192-X","volume":"149","author":"G Marchese","year":"2004","unstructured":"Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L (2004a) Haloperidol versus risperidone on rat \u201cearly onset\u201d vacuous chewing. Behav Brain Res 149:9\u201316","journal-title":"Behav Brain Res"},{"key":"33_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2003.10.005","volume":"483","author":"G Marchese","year":"2004","unstructured":"Marchese G, Bartholini F, Ruiu S, Casti P, Casu GL, Pani L (2004b) Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur J Pharmacol 483:65\u201369","journal-title":"Eur J Pharmacol"},{"key":"33_CR40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10401230490281410","volume":"16","author":"PS Masan","year":"2004","unstructured":"Masan PS (2004) Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 16:3\u201313","journal-title":"Ann Clin Psychiatry"},{"key":"33_CR41","first-page":"388","volume":"50","author":"RS McIntyre","year":"2004","unstructured":"McIntyre RS, Mancini DA, Lin P, Jordan J (2004) Treating bipolar disorder. Evidence-based guidelines for family medicine. Can Fam Physician 50:388\u2013394","journal-title":"Can Fam Physician"},{"key":"33_CR42","first-page":"238","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pK i values. J Pharmacol Exp Ther 251:238\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004714-199906000-00002","volume":"19","author":"G Muscettola","year":"1999","unstructured":"Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P (1999) Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 19:203\u2013208","journal-title":"J Clin Psychopharmacol"},{"key":"33_CR44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/jm00001a007","volume":"38","author":"J Nozulak","year":"1995","unstructured":"Nozulak J, Kalkman HO, Floersheim P, Hoyer D, Schoeffter P, Buerki HR (1995) (+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo[1,7- bc][2,6]-naphthyridine: a 5-HT2C\/2B receptor antagonist with low 5-HT2A receptor affinity. J Med Chem 38:28\u201333","journal-title":"J Med Chem"},{"key":"33_CR45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF02245863","volume":"119","author":"A Plech","year":"1995","unstructured":"Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berl) 119:466\u2013473","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","volume":"23","author":"M Pompeiano","year":"1994","unstructured":"Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163\u2013178","journal-title":"Brain Res Mol Brain Res"},{"key":"33_CR47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/sj.bjp.0702350","volume":"126","author":"C Reavill","year":"1999","unstructured":"Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126:572\u2013574","journal-title":"Br J Pharmacol"},{"key":"33_CR48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00427326","volume":"85","author":"NM Rupniak","year":"1985","unstructured":"Rupniak NM, Jenner P, Marsden CD (1985) Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology (Berl) 85:71\u201379","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00178501","volume":"88","author":"NM Rupniak","year":"1986","unstructured":"Rupniak NM, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 88:403\u2013419","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR50","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0301-0082(98)00053-7","volume":"56","author":"JD Salamone","year":"1998","unstructured":"Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591\u2013611","journal-title":"Prog Neurobiol"},{"key":"33_CR51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1749-6632.1990.tb16885.x","volume":"600","author":"E Sanders-Bush","year":"1990","unstructured":"Sanders-Bush E, Tsutsumi M, Burris KD (1990) Serotonin receptors and phosphatidylinositol turnover. Ann N Y Acad Sci 600:224\u2013235 (discussion 235\u20136)","journal-title":"Ann N Y Acad Sci"},{"key":"33_CR52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02257414","volume":"111","author":"RE Steinpreis","year":"1993","unstructured":"Steinpreis RE, Baskin P, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology (Berl) 111:99\u2013105","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02431533","volume":"96","author":"BR Stewart","year":"1988","unstructured":"Stewart BR, Jenner P, Marsden CD (1988) The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat. Psychopharmacology (Berl) 96:55\u201362","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR54","first-page":"1374","volume":"266","author":"CA Stockmeier","year":"1993","unstructured":"Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374\u20131384","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1092852900008129","volume":"8","author":"CA Tamminga","year":"2003","unstructured":"Tamminga CA (2003) The science of antipsychotics: mechanistic insight. CNS Spectr 8:5\u20139","journal-title":"CNS Spectr"},{"issue":"Suppl 11","key":"33_CR56","first-page":"11","volume":"65","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Profenno LA, Ismail MS (2004) Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 65(Suppl 11):11\u201315","journal-title":"J Clin Psychiatry"},{"key":"33_CR57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23\u201345","journal-title":"CNS Drugs"},{"key":"33_CR58","first-page":"594","volume":"38","author":"M Teitler","year":"1990","unstructured":"Teitler M, Leonhardt S, Weisberg EL, Hoffman BJ (1990) 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes. Mol Pharmacol 38:594\u2013598","journal-title":"Mol Pharmacol"},{"key":"33_CR59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/j.1875-9114.1994.tb02851.x","volume":"14","author":"ME Tonda","year":"1994","unstructured":"Tonda ME, Guthrie SK (1994) Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 14:543\u2013560","journal-title":"Pharmacotherapy"},{"key":"33_CR60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0149-7634(02)00008-8","volume":"26","author":"P Turrone","year":"2002","unstructured":"Turrone P, Remington G, Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 26:361\u2013380","journal-title":"Neurosci Biobehav Rev"},{"key":"33_CR61","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/sj.npp.1300233","volume":"28","author":"P Turrone","year":"2003","unstructured":"Turrone P, Remington G, Kapur S, Nobrega JN (2003a) Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 28:1433\u20131439","journal-title":"Neuropsychopharmacology"},{"key":"33_CR62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","volume":"165","author":"P Turrone","year":"2003","unstructured":"Turrone P, Remington G, Kapur S, Nobrega JN (2003b) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 165:166\u2013171","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF02244220","volume":"101","author":"JL Waddington","year":"1990","unstructured":"Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl) 101:431\u2013447","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR64","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002130000466","volume":"150","author":"ML Wadenberg","year":"2000","unstructured":"Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422\u2013429","journal-title":"Psychopharmacology (Berl)"},{"key":"33_CR65","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","volume":"25","author":"ML Wadenberg","year":"2001","unstructured":"Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001) Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633\u2013641","journal-title":"Neuropsychopharmacology"},{"key":"33_CR66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/(SICI)1096-9861(19960701)370:3<405::AID-CNE10>3.0.CO;2-R","volume":"370","author":"RP Ward","year":"1996","unstructured":"Ward RP, Dorsa DM (1996) Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 370:405\u2013414","journal-title":"J Comp Neurol"},{"key":"33_CR67","first-page":"9","volume":"91","author":"T Wichmann","year":"2003","unstructured":"Wichmann T, DeLong MR (2003) Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 91:9\u201318","journal-title":"Adv Neurol"},{"key":"33_CR68","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1046\/j.1471-4159.1997.69041449.x","volume":"69","author":"WA Wolf","year":"1997","unstructured":"Wolf WA, Schutz LJ (1997) The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J Neurochem 69:1449\u20131458","journal-title":"J Neurochem"},{"key":"33_CR69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ddr.1208","volume":"54","author":"MD Wood","year":"2001","unstructured":"Wood MD, Heidbreder C, Reavill C, Ashby CR Jr, Middlemiss DN (2001) 5-HT2C receptor antagonists: potential in schizophrenia. Drug Dev Res 54:88\u201394","journal-title":"Drug Dev Res"},{"key":"33_CR70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ajhp\/57.3.238","volume":"57","author":"JA Worrel","year":"2000","unstructured":"Worrel JA, Marken PA, Beckman SE, Ruehter VL (2000) Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm 57:238\u2013255","journal-title":"Am J Health-Syst Pharm"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-005-0033-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-005-0033-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-005-0033-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T10:28:00Z","timestamp":1706351280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-005-0033-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,29]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1007\/s00213-005-0033-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,29]]}}}